Cresco Labs (OTCMKTS:CRLBF) Cut to Hold at Atb Cap Markets

Atb Cap Markets lowered shares of Cresco Labs (OTCMKTS:CRLBF) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks.com reports. Atb Cap Markets also issued estimates for Cresco Labs’ FY2025 earnings at ($0.07) EPS.

A number of other research firms also recently weighed in on CRLBF. Needham & Company LLC reissued a “hold” rating on shares of Cresco Labs in a research note on Monday, August 12th. Cormark lowered Cresco Labs from a “moderate buy” rating to a “hold” rating in a research report on Monday, November 11th. Finally, Roth Capital upgraded shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $2.50.

Cresco Labs Price Performance

Cresco Labs stock opened at $1.00 on Monday. The business’s 50-day simple moving average is $1.38 and its 200 day simple moving average is $1.57. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. The stock has a market cap of $488.14 million, a price-to-earnings ratio of -5.00 and a beta of 1.73. Cresco Labs has a 12-month low of $1.00 and a 12-month high of $2.65.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.